Breaking News
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
October 22, 2018 - Duration of respiratory disturbances may better predict mortality risk from OSA
October 22, 2018 - Free phone app helps low-income obese patients to lose weight
October 22, 2018 - Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers
October 22, 2018 - FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma
October 22, 2018 - Compression Collar May Protect Brain of Female Soccer Players
October 22, 2018 - Technique visualizes neuron communication
October 22, 2018 - Advancement in medical imaging methods for health care
October 22, 2018 - Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis
October 22, 2018 - Immunotherapy increases survival in some patients with metastatic triple negative breast cancer
October 22, 2018 - Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma
October 22, 2018 - LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer
October 22, 2018 - Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
Delays Raise Death Risk in Kids with Status Epilepticus

Delays Raise Death Risk in Kids with Status Epilepticus

image_pdfDownload PDFimage_print

Action Points

  • Delay of ≥10 minutes after seizure onset in first-line benzodiazepine treatment of pediatric patients with refractory convulsive status epilepticus (SE) is associated with adverse short-term outcomes, including death, more frequent use of continuous infusions, longer seizure duration, and more frequent hypotension.
  • Note that these findings may change the perception of acute seizure and SE treatment, converting it into an extremely time-sensitive emergency similar to stroke or other cardiovascular events.

Delayed first-line treatment of refractory convulsive status epilepticus (SE) led to a higher frequency of death, a 5-year observational study from the Pediatric Status Epilepticus Research Group found.

Pediatric patients who received first-line benzodiazepine treatment 10 minutes or more after SE onset had a much higher chance of death (adjusted OR 11.0), greater odds of receiving continuous infusion (adjusted OR 1.8), longer convulsive seizure durations (adjusted OR 2.6), and more frequent hypotension (adjusted OR 2.3), reported Tobias Loddenkemper, MD, director of Clinical Epilepsy Research at Boston Children’s Hospital. and colleagues.

First-line treatment delays also were linked to delays in administering second- and third-line treatments.

“These findings may change the perception of acute seizure and status epilepticus treatment, tentatively converting it into an extremely time-sensitive emergency that is similar to stroke or other cardiovascular events,” the team wrote online in JAMA Neurology.

“This is the first pediatric study on refractory convulsive SE that demonstrates a link between delayed treatment and poor outcomes and suggests that timely treatment may be a method to prevent or improve such outcomes,” commented Anup D. Patel, MD, section chief of Neurology at Nationwide Children’s Hospital in Columbus, OH, writing in an accompanying editorial.

“Status epilepticus is life threatening and affects a high percentage of children. Both short-term and long-term morbidity and mortality risks are present for children who experience SE. Methods to improve these outcomes are thus desperately needed.”

Current SE treatment protocols recommend that patients receive first-line treatment — a benzodiazepine — within 5 to 10 minutes of seizure onset. This usually is followed by a second-line treatment of a non-benzodiazepine anti-seizure medication 10 to 20 minutes later. If SE persists, patients may receive a third-line treatment — anesthetic agents by continuous infusion — within 30 to 70 minutes of seizure onset.

The rationale is to stop seizures quickly and reduce the risk of brain damage and other complications. Studies have shown that seizures usually last less than 10 minutes; seizures lasting longer often do not stop spontaneously.

While time to treatment has been associated independently with SE duration, the effects on other outcome measurements like death were unknown.

To discover how timing mattered, Loddenkemper et al performed an observational study of 218 children admitted with refractory convulsive SE to 11 pediatric tertiary hospitals in the United States from June 1, 2011, to July 31, 2016. Patients were stratified into two groups: those who received timely first-line benzodiazepine (i.e., given within less than 10 minutes of seizure onset); and those who received treatment within 10 or more minutes.

Patients were ages 1 month to 21 years, had focal or generalized convulsive epileptic seizures at onset, and had treatment failure with two or more anti-seizure medications or started continuous infusion for seizure control.

The median age of the group was 4, and 53.2% were male. Of the 218 patients studied, 33.9% received first-line benzodiazepine treatment in less than 10 minutes, and 66.1% received it in 10 minutes or more. In 63.8% of patients, refractory convulsive SE started in a pre-hospital setting.

The median time to first-line benzodiazepine treatment was 17 minutes; it was longer in the pre-hospital group than the in-hospital cohort (25 minutes versus 8 minutes). The median time to the first administration of non-benzodiazepine anti-seizure medications was 63 minutes — that, too, was longer for the pre-hospital group (82 minutes) than the in-hospital group (40 minutes).

During hospital admission, seven patients (3.2%) died. All seven received untimely first-line benzodiazepine treatment, and five of the seven had pre-hospital SE onset. Multivariate analysis showed that untimely first-line benzodiazepine treatment had an adjusted OR of death of 11.0 (95% CI 1.43 to ∞; P=0.02.).

About half of the patients in the study — 112, or 51.4% — received a continuous infusion; of these, 71.4% had received untimely first-line treatment (P=0.09). The untimely treatment group was more likely to receive one or more continuous infusions (adjusted OR, 1.8; 95% CI 1.01-3.36; P=0.047).

The median convulsion duration was 48.5 minutes longer for patients who received untimely first-line benzodiazepine treatment (91 versus 139.5 minutes; P=0.03).

More work is needed to improve outcomes, especially in the pre-hospital setting, Patel noted: “Evidence-based guidelines exist for the pre-hospital treatment of seizures and most emergency medical services have independent protocols, but it is not known if these guidelines are implemented uniformly by emergency medical services personnel.

“Standardization of these protocols using guidelines may improve outcomes and is a good first step.”

The study has several limitations, the researchers noted. They did not determine the association between the dose of benzodiazepine and outcomes, and the small number of overall deaths in the study limited the number of confounders in the analysis; other confounders may have influenced mortality and other outcomes. In the pre-hospital setting, times to treatment were based on information provided by families, although the researchers corroborated data with emergency medical services reports and medical records when available.

In addition, the team said, the findings do not include patients whose seizures spontaneously stopped, or stopped after medication before coming to the hospital; the findings apply only to pediatric patients with refractory convulsive SE.

The study and the Pediatric Status Epilepticus Research Group consortium of 11 tertiary pediatric hospitals in the United States are funded by the Epilepsy Research Fund and the Pediatric Epilepsy Research Foundation.

The researchers reported financial relationships with Ovation Pharmaceuticals, King Pharmaceuticals, PRA International/Eisai, Johnson & Johnson, Lily, GlaxoSmithKline, Pfizer, Siemens, General Electric, Supernus, AssureX Health, Sage Therapeutics, GWPharm, Novartis, Lundbeck, Upsher-Smith, Acorda, and Zogenix.

Patel reported financial relationships with Greenwich Biosciences, UCB Pharma, Supernus, LivaNova, and Upsher-Smith.

2018-01-23T14:00:00-0500

Tagged with:

About author

Related Articles